MXPA04007556A - Estimulacion de cpt-1 como medio para reducir peso. - Google Patents

Estimulacion de cpt-1 como medio para reducir peso.

Info

Publication number
MXPA04007556A
MXPA04007556A MXPA04007556A MXPA04007556A MXPA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A MX PA04007556 A MXPA04007556 A MX PA04007556A
Authority
MX
Mexico
Prior art keywords
cpt
agent
administered
fatty acid
amount sufficient
Prior art date
Application number
MXPA04007556A
Other languages
English (en)
Inventor
Ronnett Gabriele
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of MXPA04007556A publication Critical patent/MXPA04007556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pediatric Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Esta invencion proporciona metodos y composiciones para inducir la perdida de peso y mantener el peso optimo que comprenden administrar un agentes que estimula la actividad de la carnitina palmitoil transferasa-1 (CPT-1) al paciente que la necesita, incluyendo pacientes humanos. Estos metodos no requieren la inhibicion de la sintesis de acidos grasos. En particular, esta invencion proporciona metodos para desarrollar terapias que selectivamente potencian la oxidacion de acidos grasos, incrementan la produccion de energia y reducen la adiposidad mientras que preservan la masa sin grasa, a traves de la estimulacion farmacologica de la actividad de CPT-1. En una modalidad preferida, el agente es administrado en una cantidad suficiente para incrementar la oxidacion de acidos grasos. En otra modalidad preferida, el agente es administrado en una cantidad suficiente para antagonizar la inhibicion de la malonil CoA de CPT-1. Aun, en otra modalidad preferida, el agente es administrado en una cantidad suficiente para incrementar el nivel de la malonil CoA.
MXPA04007556A 2002-02-08 2003-02-10 Estimulacion de cpt-1 como medio para reducir peso. MXPA04007556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Publications (1)

Publication Number Publication Date
MXPA04007556A true MXPA04007556A (es) 2005-12-05

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007556A MXPA04007556A (es) 2002-02-08 2003-02-10 Estimulacion de cpt-1 como medio para reducir peso.

Country Status (12)

Country Link
US (4) US20050143467A1 (es)
EP (1) EP1471906A4 (es)
JP (2) JP2005523270A (es)
KR (1) KR20040082417A (es)
CN (1) CN1313089C (es)
AU (2) AU2003215111A1 (es)
BR (1) BR0307421A (es)
CA (1) CA2474884A1 (es)
EA (1) EA007029B1 (es)
IL (1) IL163312A (es)
MX (1) MXPA04007556A (es)
WO (1) WO2003066043A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
WO2004005277A1 (en) * 2002-07-09 2004-01-15 Fasgen, Inc. Novel compunds, pharmaceutical compositions containing same, and methods of use for same
US20080119548A1 (en) * 2004-03-18 2008-05-22 Ronnett Gabrielle V Control Of Feeding Behavior By Changing Neuronal Energy Balance
RU2006146051A (ru) * 2004-05-26 2008-07-10 Фасджен Новые соединения, фармацевтические композиции на их основе и способы применения
AU2006256825B2 (en) * 2005-06-06 2010-02-18 F. Hoffmann-La Roche Ag Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPT1) inhibitors
US20100168218A1 (en) * 2005-07-26 2010-07-01 Kuhajda Francis P Method of reducing food intake
EP1760147B1 (en) * 2005-08-29 2008-12-24 F. Hoffmann-La Roche Ag Crystal structures of carnitine palmitoyltransferase-2 (CPT-2) and uses thereof
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
KR20020060736A (ko) * 1999-11-12 2002-07-18 추후보정 세포내 말로닐 조효소 에이의 수준을 증가시킴에 의한암의 치료 방법
CA2400136A1 (en) * 2000-02-16 2001-08-23 The Johns Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
US20060241177A1 (en) 2002-07-01 2006-10-26 Kuhadja Francis P Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2004005277A1 (en) 2002-07-09 2004-01-15 Fasgen, Inc. Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
BR0307421A (pt) 2004-12-28
EP1471906A1 (en) 2004-11-03
US20050106217A1 (en) 2005-05-19
IL163312A (en) 2011-12-29
CN1638758A (zh) 2005-07-13
US7459481B2 (en) 2008-12-02
EA200401052A1 (ru) 2005-02-24
US20090124684A1 (en) 2009-05-14
JP2010047594A (ja) 2010-03-04
EP1471906A4 (en) 2006-02-01
CN1313089C (zh) 2007-05-02
CA2474884A1 (en) 2003-08-14
US20050143467A1 (en) 2005-06-30
AU2008249144A1 (en) 2008-12-11
JP2005523270A (ja) 2005-08-04
EA007029B1 (ru) 2006-06-30
AU2003215111A1 (en) 2003-09-02
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
US20070087037A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
HUT62798A (en) Process for producing pharmaceutical composition with slimming activity
PL363452A1 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
NZ507730A (en) Hematopoietic stimulation
ES2129013A1 (es) Utilizacion de la vitamina c o de sus derivados o analogos para estimular la sintesis de la elastina cutanea.
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
MX9702527A (es) Metodo y composicion de sintesis de oxido nitrico estimulante.
MXPA04007556A (es) Estimulacion de cpt-1 como medio para reducir peso.
AU4258101A (en) Combination therapies with vascular damaging activity
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
CN104546623A (zh) 一种含有海螵蛸的牙膏
PL323363A1 (en) Biaromatic propynyl or dienyl compounds
Pisani et al. Interaction of carbamazepine‐10, 11‐epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study
US6500857B1 (en) Subcutaneous muscle treatment using electronic stimulation and topical compositions
DE502005001398D1 (de) Hautpflegeprodukt enthaltend Ursolsäure und Ginkgo-Extrakt
TW200517119A (en) Method of treatment using interferon-tau
IL151627A0 (en) Divided dose therapies with vascular damaging activity
TW200613032A (en) Uses for augmenting bone
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
HUP0002643A2 (hu) Szívrendellenességek kezelése és megelőzése SSRI-k alkalmazásával
JP6656890B2 (ja) フィラグリン産生促進剤
WO2000015783A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE
CA2405265A1 (en) Method of preventing or treating diabetes
RU2014102651A (ru) Способ лечения зависимости от табака
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
RU2002113429A (ru) Способ лечения псориаза

Legal Events

Date Code Title Description
FG Grant or registration